Abstracts Archive - Page 916 of 2607 - ACR Meeting Abstracts

Abstract Number: 1194 • ACR Convergence 2020
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Fabienne Louis-Sidney², Benjamin Granger³, Joanna Kedra⁴, Marie-Pierre Debray⁵, Esther Ebstein¹, Raphaël Borie⁶, Arnaud Constantin⁷, Bernard Combe⁸, Rene-Marc Flipo⁹, Xavier Mariette¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Guillermo Carvajal Alegria¹³, Jean Sibilia¹⁴, Francis Berenbaum¹⁵, Caroline Kannengiesser¹⁶, Bruno Crestani⁶, Catherine Boileau¹⁶, Bruno Fautrel¹⁷ and Philippe Dieude¹⁸, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Paris, France, ⁴Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁶Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁷Hospital Pierre Paul Riquet, Toulouse, France, ⁸University of Montpellier, Montpellier, France, ⁹Lille University Hospital, Lille, France, ¹⁰Paris-Sud University, Rueil-Malmaison, France, ¹¹University Hospital of Rouen, Rouen, France, ¹²Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹³CHU de Brest, Service de Rhumatologie, Brest, France, ¹⁴CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁵AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁶Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) detected in 20 to 60% of patients with RA on high-resolution computed-tomography…
Abstract Number: 1195 • ACR Convergence 2020
MUC5B rs35705950 and Rheumatoid Arthritis Associated Interstitial Lung Disease Progression
Pierre-Antoine Juge¹, Joshua Solomon², Romain Garofoli³, Joyce S. Lee⁴, Fabienne Louis-Sidney⁵, Esther Ebstein¹, Jorge Rojas-Serrano⁶, Montserrat I. Gonzalez-Perez⁶, Mayra Mejia⁶, Ivette Buendia-Roldan⁶, Ramces Falfan-Valencia⁷, Enrique Ambrocio-Ortiz⁷, Effrosyni Manali⁸, Spyros A. Papiris⁸, Theofanis Karageorgas⁹, Dimitrios Boumpas⁹, Katarina Antoniou¹⁰, Coline H.M. van Moorsel¹¹, Joanne van Der Vis¹¹, Yaël A. de Man¹¹, Jan C. Grutters¹¹, Caroline Kannengiesser¹², Raphaël Borie¹³, Lidwine Wemeau-Stervinou¹⁴, Rene-Marc Flipo¹⁵, Hilario Nunes¹⁶, Yurdagul Uzunhan¹⁷, Dominique Valeyre¹⁸, Nathalie Saidenberg Kermanac'h¹⁹, Marie-Christophe Boissier²⁰, Christophe Richez²¹, Thierry Schaeverbeke²², Tracy J. Doyle²³, Paul Wolters²⁴, Marie-Pierre Debray²⁵, Catherine Boileau¹², Raphaël Porcher²⁶, Bruno Crestani¹³, David A. Schwartz⁴ and Philippe Dieude²⁷, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²National Jewish Health, Denver, CO, ³Hôpital Cochin, Service de Rééducation, Paris, Paris, France, ⁴Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA, Aurora, CO, ⁵Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ⁶Interstitial Lung Disease & Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, México City, México, Mexico, Mexico, ⁷HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas. Mexico City, Mexico, Mexico, Mexico, ⁸2nd Pulmonary Medicine Department, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁹Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, University Hospital of Athens "Attikon", National and Kapodistrian University of Athens, Greece, Athens, Greece, ¹⁰PS Department of Respiratory Medicine & Laboratory of Molecular & Cellular Pneumonology, Faculty of Medicine, University of Crete, Crete, Greece, Heraklion, Greece, ¹¹St Antonius ILD center of excellence, St Antonius ziekenhuis, Nieuwegein, The Netherlands, Nieuwegein, Netherlands, ¹²Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ¹⁴CHRU de Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence des maladies pulmonaires rares, FHU IMMINENT, Lille, France, Lille, France, ¹⁵Lille University Hospital, Lille, France, ¹⁶Department of Pulmonology, Hôpital Avicenne, APHP, Bobigny, France, Bobigny, France, ¹⁷Hôpital Avicennes, Service de Pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁸Hôpital Avicenne, Service de pneumologie, AP-HP, Bobigny, Bobigny, France, ¹⁹Hôpital Avicennes, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²⁰Hôpital Avicenne, Service de Rhumatologie, AP-HP, Bobigny, Bobigny, France, ²¹Rheumatology Hospital, Pelligrin Hospital, Bordeaux University Hospital, Bordeaux, France, ²²CHU de Bordeaux, Service de Rhumatologie, Bordeaux, France, ²³Brigham and Women's Hospital, West Roxbury, MA, ²⁴University of California, San Francisco, San Francisco, CA, ²⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²⁶Centre d’Epidémiologie Clinique, AP-HP, Hôpital Hôtel-Dieu, F-75004 Paris, France, Paris, France, ²⁷Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) sharephenotypic and genotypic similarities. Recently, in a large international genetic association…
Abstract Number: 1196 • ACR Convergence 2020
Associations of Biological Sex with Interstitial Lung Disease in Patients with Rheumatoid Arthritis Are Independent of Other Known Risk Factors
Austin Wheeler¹, Gail Kerr², Ilona Jileaeva³, Asha Krishna⁴, Bryant England¹, Harlan Sayles¹, Geoffrey Thiele¹, Jill Poole¹, Alison Petro¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Washington DC VA Medical Center, Washington, DC, ³Howard University Hospital, Washington, DC, ⁴Washington, D.C. VAMC, Washington, DC
Background/Purpose: Extra-articular manifestations of rheumatoid arthritis (RA), such as nodules and interstitial lung disease (ILD), portend poor outcomes and are more common in men than…
Abstract Number: 1197 • ACR Convergence 2020
Biomarkers for Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review
Dawson Shaver¹, Daniel Van Kalsbeek¹, Ariadne Ebel¹, Daniel Hershberger¹, Cynthia Schmidt¹, Jill Poole¹, Geoffrey Thiele¹, Dana Ascherman², Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is among the most frequent and severe extra-articular manifestations of RA, contributing significantly to the excess mortality among RA…
Abstract Number: 1198 • ACR Convergence 2020
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Vanessa Kronzer¹, Weixing Huang², Paul Dellaripa³, Sicong Huang⁴, Vivi Feathers², Bing Lu⁵, Christine Iannaccone⁶, Ritu Gill⁷, Hiroto Hatabu⁸, Mizuki Nishino⁸, Cynthia Crowson⁹, John Davis¹, Michael Weinblatt⁴, Nancy Shadick¹⁰, Tracy J. Doyle¹¹ and Jeffrey Sparks¹⁰, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Newton, MA, ⁶Division of General Internal Medicine; Brigham and Women’s Hospital, Topsfield, MA, ⁷Department of Radiology; Harvard Medical School, Beth Israel Deaconess Medical Center, Topsfield, MA, ⁸Department of Radiology; Brigham and Women’s Hospital, Boston, ⁹Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ¹⁰Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ¹¹Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Despite the known excess mortality of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its association with certain lifestyle factors such as obesity and future prediction…
Abstract Number: 1199 • ACR Convergence 2020
Prevalence of Subclinical Interstitial Lung Disease After a Mean Rheumatoid Arthritis Duration of 13 Years: Results from the French ESPOIR Cohort
Pierre-Antoine Juge¹, Marie-Pierre Debray², Esther Ebstein¹, Raphaël Borie³, Arnaud Constantin⁴, Bernard Combe⁵, Bruno Fautrel⁶, Rene-Marc Flipo⁷, Xavier Mariette⁸, Olivier Vittecoq⁹, Alain Saraux¹⁰, Guillermo Carvajal Alegria¹¹, Jean Sibilia¹², Francis Berenbaum¹³, Bruno Crestani³ and Philippe Dieude¹⁴, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ³Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁴Hospital Pierre Paul Riquet, Toulouse, France, ⁵University of Montpellier, Montpellier, France, ⁶Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁷Lille University Hospital, Lille, France, ⁸Paris-Sud University, Rueil-Malmaison, France, ⁹University Hospital of Rouen, Rouen, France, ¹⁰Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹¹CHU de Brest, Service de Rhumatologie, Brest, France, ¹²Department of rheumatology, University Hospitals of Strasbourg and French National Reference Center for Rare Auto-immune diseases, Strasbourg, France, ¹³AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁴Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is a frequent extra-articular manifestation of rheumatoid arthritis (RA). It is associated with a high morbi-mortality. However, the exact prevalence…
Abstract Number: 1200 • ACR Convergence 2020
Serum Anti-PAD4 and Anti-PAD3/4XR Antibodies in Rheumatoid Arthritis Associated-Interstitial Lung Disease Are Associated with Better Lung Function
Tim Wilson¹, Joshua Solomon², Jeffrey Swigris², Erika Darrah³ and M Kristen Demoruelle¹, ¹University of Colorado, Denver, CO, ²National Jewish Health, Denver, CO, ³Division of Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) associated-interstitial lung disease (ILD) affects approximately 10% of RA patients. It is a leading cause of morbidity and mortality, which is…
Abstract Number: 1201 • ACR Convergence 2020
Effect of Filgotinib on Pain in Patients with Rheumatoid Arthritis: Results from Phase 3 Clinical Trials
Peter Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Beatrix Bartok⁵, Ken Hasegawa⁵, Shangbang Rao⁵, Sander Strengholt⁶ and Rene Westhovens⁷, ¹Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, & Immunology, University of California San Diego Medical School, San Diego, CA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos BV, Leiden, Netherlands, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: RA patients (pts) often suffer substantial pain despite ongoing treatment (tx) and regard pain control as a top tx goal. Filgotinib (FIL)—a potent, oral…
Abstract Number: 1202 • ACR Convergence 2020
Cannabis Use Assessment and Its Impact on Pain in Rheumatic Diseases: A Systematic Review and Meta-analysis
Manon Guillouard¹, Nicolas Authier¹, Bruno Pereira¹, Martin Soubrier¹ and Sylvain Mathieu¹, ¹CHU Gabriel Montpied, Clermont-Ferrand, France
Background/Purpose: Despite classic analgesic or effective treatments in rheumatic diseases, such as synthetic Disease Modifying Anti-Rheumatic Drugs in rheumatoid arthritis (RA), patients remain in pain…
Abstract Number: 1203 • ACR Convergence 2020
Analysis of the Impact of Tofacitinib Treatment on Weight in Patients with Rheumatoid Arthritis
Jürgen Wollenhaupt¹, Jacques Morel², Claire Daien³, Adeline Ruyssen-Witrand⁴, Cédric Lukas³, Christophe Richez⁵, Andrea Shapiro⁶, Douglass S Chapman⁷, Magali Cros⁸, Jose L Rivas⁹ and Gustavo Citera¹⁰, ¹Struenseehaus Centre for Rheumatology and Clinical Immunology, Hamburg, Germany, ²Rheumatology department, CHU Montpellier and University of Montpellier, Montpellier, France, ³CHU Montpellier and University of Montpellier, Montpellier, France, ⁴Hôpital Purpan, CHU Toulouse, Toulouse, France, ⁵Groupe Hospitalier Pellegrin-CHU de Bordeaux, Bordeaux, France, ⁶Pfizer Inc, Peapack, NJ, ⁷Pfizer Inc, New York, NY, ⁸Pfizer Inc, Paris, France, ⁹Pfizer SLU, Madrid, Spain, ¹⁰Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose: A prior post hoc analysis of tofacitinib clinical trial data reported improvements in RA outcomes with tofacitinib vs placebo (PBO) through Month (M)6, regardless…
Abstract Number: 1204 • ACR Convergence 2020
Use of Multi-Biomarker Disease Activity Scores to Assess Biosimilarity in a Phase 3 Randomized Controlled Trial Comparing Biosimilar Infliximab-qbtx (PF‑06438179/GP1111) with EU-Sourced Reference Infliximab in Patients with Active RA
Jonathan Kay¹, Daniel Alvarez², Muhammad Iftikharur Rehman³, Min Zhang⁴ and Noriko Iikuni⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Pfizer, Collegeville, PA, ³Pfizer, Andover, MA, ⁴Pfizer, La Jolla, CA, ⁵Pfizer, New York, NY
Background/Purpose: The multi-biomarker disease activity (MBDA; Vectra® DA, Myriad Genetics, Inc.) score is calculated from concentrations of 12 serum proteins to assess disease activity (DA)…
Abstract Number: 1205 • ACR Convergence 2020
Soluble Vascular Biomarkers in Rheumatoid Arthritis and Ankylosing Spondylitis: Effects of One-year Anti-TNF-α Therapy
Anita Pusztai¹, Attila Hamar², Ágnes Horváth², Katalin Gulyás², Edit Végh², Nóra Bodnár², György Kerekes², Monika Czókolyová², Szilvia Szamosi², Levente Bodoki², Katalin Hodosi², Andrea Domján², Gábor Nagy², Luis Lopez³, Ejii Matsuura⁴, Zoltán Prohászka⁵, Sándor Szántó², Zoltán Nagy², Yehuda Shoenfeld⁶, Zoltán Szekanecz² and Gabriella Szűcs², ¹University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ²University of Debrecen, Debrecen, Hungary, ³Corgenix Inc., Broomfield, CO, ⁴Okayama University, Okayama, Japan, ⁵Semmelweis University, Budapest, Hungary, ⁶Zabludowicz Center, Tel-Hashomer, Israel
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been associated with cardiovascular (CV) disease. The treatment of arthritis by tumour necrosis factor α (TNF-α)…
Abstract Number: 1206 • ACR Convergence 2020
Associations of Vascular and Bone Status in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Anita Pusztai¹, Attila Hamar², Monika Czókolyová², Katalin Gulyás², Ágnes Horváth², Edit Végh², Zsófia Pethő², Szilvia Szamosi², Emese Balogh², Nóra Bodnár², Ágnes Szentpétery³, Harjit Bhattoa², György Kerekes², Balázs Juhász², Éva Szekanecz², Katalin Hodosi², Andrea Domján², Sándor Szántó², Hennie Raterman⁴, Willem Lems⁵, Zoltán Szekanecz² and Gabriella Szűcs², ¹University of Debrecen Faculty of Medicine, Department of Rheumatology, Debrecen, Hungary, ²University of Debrecen, Debrecen, Hungary, ³Uppsala University Hospital, Uppsala, Sweden, ⁴Northwest Clinics, Alkmaar, Netherlands, ⁵Amsterdam Rheumatology and Immunology Centre, Amsterdam, Netherlands
Background/Purpose: Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the ageing population, even more in patients with inflammatory rheumatic diseases, such as…
Abstract Number: 1207 • ACR Convergence 2020
Impact of Body Mass Index on Clinical Responses of Novel Subcutaneous Infliximab (CT-P13 SC) in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Part 2 of Phase I/III Randomized Controlled Trial
DaeHyun Yoo¹, Rene Westhovens², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, NooRi Han⁹ and YooBin Jung⁹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ²University Hospitals Leuven, Belgium, Leuven, Belgium, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: In the analysis of PLANETRA, a Phase III randomized controlled trial (RCT), no significant association was found between body mass index (BMI) and clinical…
Abstract Number: 1208 • ACR Convergence 2020
Utility of Measuring the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Results from a Multicenter, Randomized Controlled Pivotal Trial
Rene Westhovens¹, DaeHyun Yoo², Piotr Wiland³, Marek Zawadzki⁴, Delina Ivanova⁵, Alfredo Berrocal Kasay⁶, Elias Chalouhi⁷, Eva Balázs⁸, SangJoon Lee⁹, SungHyun Kim⁹, JeeHye Suh⁹, ChanKyoung Hwang⁹ and DaeSeok Choi⁹, ¹University Hospitals Leuven, Belgium, Leuven, Belgium, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ³Medical Univeristy, Wroclaw, Poland, ⁴Medical Univeristy, Dpt of Rheumatology , Wroclaw, Wroclaw, Poland, ⁵Diagnostic-Consultative Center Aleksandrovska EOOD, Sofia, Bulgaria, ⁶ABK Reuma SRL, LIMA, Peru, ⁷Clinica Internacional Sede Lima, Lima, Peru, ⁸Dr. Bugyi István Hospital, Szentes, Hungary, ⁹Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: Novel subcutaneous infliximab (CT-P13 SC) was developed to augment the flexibility in the therapeutic use of infliximab and non-inferiority (NI) of CT-P13 SC versus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].